Table of Contents
Section 1 Parkinson's Disease: Introductory Chapters1. A Short History of Parkinson's Disease from early 19th century and afterwards an overview2. Living with Parkinson's disease from financial to emotional3. The epidemiology of Parkinson's disease an overview4. Clinical Features of Parkinson's disease an overview5. The natural history of Parkinson's disease an overview6. The prognosis of Parkinson's disease an overview7. The neurobiology of Parkinson's disease an overview8. The pathophysiology of Parkinson's disease an overview9. Molecular and cellular mechanisms associated with Parkinson's disease synuclein, amyloid protein, oligomers and beyond10. Quality of life in Parkinson's disease11. Gait in untreated Parkinson's disease12. Levodopa-induced dyskinesias13. Tremor in Parkinson's disease14. The impact of Parkinson's disease on the family and careers
Section 2 Biomarkers and Diagnosis15. Tissue biopsies as biomarkers in Parkinson's disease16. Spinal fluid for biomarker discovery in Parkinson's disease17. Clinical biomarkers in prodromal Parkinson's disease18. The diagnosis of Parkinson's disease19. Proteomics in Parkinson's disease20. MicroRNAs as biomarkers in Parkinson's diseases21. Phenotyping in Parkinson's disease22. Diagnosis of speech disorders in Parkinson's disease23. Identifying dementia in Parkinson's disease24. Diagnosis of sleep disturbances in Parkinson's disease25. Diagnosis of Parkinson's disease using magnetic resonance imaging26. Use of ultrasound as a diagnostic tool in Parkinson's disease27. Use of single-photon emission computerized tomography (SPECT) as a diagnostic tool in Parkinson's disease28. Use of positron emission tomography (PET) as a diagnostic tool in Parkinson's disease
Section 3 Pharmacological Treatments for Parkinson's Disease29. Dopamine Agonists and Parkinson's disease an overview30. Management with Levodopa in Parkinson's disease31. Management with ripinirole in Parkinson's disease32. Management with pramipexole in Parkinson's disease33. Management with rotigotine in Parkinson's disease34. Management with apomorphine in Parkinson's disease35. Management with MAO-B Inhibitors in Parkinson's disease36. Management with COMT inhibitors in Parkinson's disease37. Management with anticholinergics in Parkinson's disease38. Management with amantadine in Parkinson's disease
Section 4 Novel and Non-Pharmacological Therapies For Parkinson's Disease39. Treatment with chelator in Parkinson's disease40. Treatment with deep brain stimulation in Parkinson's disease41. Olive leaf extract usage as an antioxidant and applications to Parkinson's disease42. Treatment with Vitamin D for Parkinson's disease43. Chemogenetics and applications for Parkinson's disease44. Flavonoids and naringin usage in Parkinson's disease45. Stem cells and applications to Parkinson's disease46. Treatment with cannabis for Parkinson's disease47. Treating sleep problems in Parkinson's disease48. Perioperative treatments of Parkinson's disease49. Exercise and Parkinson's disease50. Molecular aspects: CB2 receptors and neuroprotection in Parkinson's disease